Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Feb 2006

Loveland Bruce E, Zhao Anne, White Shane, Gan Hui, Hamilton Kate, Xing Pei-Xiang, Pietersz Geoffrey A, Apostolopoulos Vasso, Vaughan Hilary, Karanikas Vaios, Kyriakou Peter, McKenzie Ian F C, Mitchell Paul L R

Abstract excerpt

PURPOSE: Tumor antigen-loaded dendritic cells show promise for cancer immunotherapy. This phase I study evaluated immunization with autologous dendritic cells pulsed with mannan-MUC1 fusion protein (MFP) to treat patients with advanced malignancy. EXPERIMENTAL DESIGN: Eligible patients had adenocarcinoma expressing MUC1, were of performance status 0 to 1, with no autoimmune disease. Patients underwent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mannans
Share to Antigens, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Vaccines

Share to Dendritic Cells

Share to Dose-Response Relationship, Immunologic

Share to Immunotherapy

Share to Mucin-1

Share to Mucins

Source

Identifiers

PMID: 16467101
DOI: 10.1158/1078-0432.CCR-05-1574

Genes

MUC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.PMID 16467101Read ↗

A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer.Semantic proximity Read ↗

Restoring tumor immunogenicity with dendritic cell reprogrammingSemantic proximity Read ↗

Dendritic-Tumor Fusion Cell-Based Cancer VaccinesSemantic proximity Read ↗

Cellular Immunotherapy with Dendritic Cells in Cancer: Current StatusSemantic proximity Read ↗

Glycyrrhiza uralensis polysaccharides as a Dendritic Cell-Based Vaccine Adjuvant: Enhanced Cancer Immunotherapy Combined with PD-1 BlockadeSemantic proximity Read ↗

Human dendritic cells transfected with amplified MUC1 mRNA stimulate cytotoxic T lymphocyte responses against pancreatic cancer in vitro.Semantic proximity Read ↗

Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report.Semantic proximity Read ↗

Glycyrrhiza uralensis polysaccharides as a DC-based Vaccine Adjuvant: Enhanced Immunotherapy Combined with PD-1 BlockadeSemantic proximity Read ↗

Dendritic cell-tumor fusion vaccine prevents tumor growth in vivo.Semantic proximity Read ↗

Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity.Semantic proximity Read ↗

Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide.Semantic proximity Read ↗

Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.